Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Chetan Bettegowda, Mark Sausen, Rebecca J. Leary et al. · Science Translational Medicine · 2014
The development of noninvasive methods to detect and monitor tumors continues to be a major challenge in oncology. We used digital polymerase chain reaction-based technologies to evaluate the ability of circulating tumor DNA (ctDNA) to detect tumors in 640 patients with various cancer types. We found that ctDNA was detectable in >75% of patients with advanced pancreatic, ovarian, colorectal, bladder, gastroesophageal, breast, melanoma, hepatocellular, and head and neck cancers, but in less than 50% of primary brain, renal, prostate, or thyroid cancers. In patients with localized tumors, ctDNA was detected in 73, 57, 48, and 50% of patients with colorectal cancer, gastroesophageal cancer, pancreatic cancer, and breast adenocarcinoma, respectively. ctDNA was often present in patients without detectable circulating tumor cells, suggesting that these two biomarkers are distinct entities. In a separate panel of 206 patients with metastatic colorectal cancers, we showed that the sensitivity of ctDNA for detection of clinically relevant KRAS gene mutations was 87.2% and its specificity was 99.2%. Finally, we assessed whether ctDNA could provide clues into the mechanisms underlying resistance to epidermal growth factor receptor blockade in 24 patients who objectively responded to therapy but subsequently relapsed. Twenty-three (96%) of these patients developed one or more mutations in genes involved in the mitogen-activated protein kinase pathway. Together, these data suggest that ctDNA is a broadly applicable, sensitive, and specific biomarker that can be used for a variety of clinical and research purposes in patients with multiple different types of cancer.
Cited by 5,044 works. doi:10.1126/scitranslmed.3007094
Authors
- Chetan Bettegowda
- Mark Sausen
- Rebecca J. Leary
- Isaac Kinde
- Yuxuan Wang
- Nishant Agrawal
- Bjarne R. Bartlett
- Hao Wang
- Brandon S. Luber
- Rhoda M. Alani
- Emmanuel S. Antonarakis
- Nilofer Saba Azad
- Alberto Bardelli
- Henry Brem
- John L. Cameron
- Clarence C. Lee
- Leslie Anne Fecher
- Gary L. Gallia
- Peter Gibbs
- Dung Thi Le
References
- High Frequency of Mutations of the PIK3CA Gene in Human Cancers
- Cancer Genome Landscapes
- Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
- Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes
- K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations
- Detection of Mutations in EGFR in Circulating Lung-Cancer Cells
- Circulating mutant DNA to assess tumor dynamics
- Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
- Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer